Cargando…

Molecular and clinical features of a potential immunotherapy target ELK3 in glioma

Glioma represents the most prevalent malignant primary brain cancer, and its treatment remains a tremendous challenge. Novel and efficient molecular targets are therefore required for improving diagnosis, survival prediction, and treatment outcomes. Additionally, some studies have shown that immunit...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Hao, Zhang, Li, Gao, Jin, Wang, Jiajing, Wang, Yihao, Xiao, Dongdong, Chai, Songshan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9333475/
https://www.ncbi.nlm.nih.gov/pubmed/35905257
http://dx.doi.org/10.1097/MD.0000000000029544
_version_ 1784758885030035456
author Xu, Hao
Zhang, Li
Gao, Jin
Wang, Jiajing
Wang, Yihao
Xiao, Dongdong
Chai, Songshan
author_facet Xu, Hao
Zhang, Li
Gao, Jin
Wang, Jiajing
Wang, Yihao
Xiao, Dongdong
Chai, Songshan
author_sort Xu, Hao
collection PubMed
description Glioma represents the most prevalent malignant primary brain cancer, and its treatment remains a tremendous challenge. Novel and efficient molecular targets are therefore required for improving diagnosis, survival prediction, and treatment outcomes. Additionally, some studies have shown that immunity is highly associated with glioma progression. Our study aimed to investigate the clinicopathological features, prognostic significance, and immunotherapeutic targetability of ELK3, a member of the erythroblast transformation-specific transcription factor family, in glioma using bioinformatics analyses. ELK3 transcript levels in glioma tissues were evaluated using the Gene Expression Omnibus and The Cancer Genome Atlas databases. Clinical and transcriptomic data of The Cancer Genome Atlas glioma patients were analyzed to identify the molecular and clinical characterizations of ELK3. The prognostic significance of ELK3 was assessed using Cox regression and Kaplan–Meier analysis. The biological pathways related to ELK3 expression were identified by gene set enrichment analysis. The relationships between ELK3 and inflammatory responses, immune cell infiltration, and immune checkpoints were explored using canonical correlation analysis and gene set variation analysis. ELK3 was upregulated in gliomas, and its high expression was correlated with advanced clinicopathologic features and unfavorable prognosis. Gene set enrichment analysis revealed that several immune-related pathways were tightly linked to high ELK3 expression. gene set variation analysis and correlograms demonstrated that ELK3 was robustly associated with inflammatory and immune responses. Correlation analyses indicated that ELK3 was positively associated with infiltrating immune cells and synergistic with several immune checkpoints. ELK3 may serve as a novel marker of poor prognosis and a potential immunotherapeutic target in glioma.
format Online
Article
Text
id pubmed-9333475
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-93334752022-08-03 Molecular and clinical features of a potential immunotherapy target ELK3 in glioma Xu, Hao Zhang, Li Gao, Jin Wang, Jiajing Wang, Yihao Xiao, Dongdong Chai, Songshan Medicine (Baltimore) Research Article Glioma represents the most prevalent malignant primary brain cancer, and its treatment remains a tremendous challenge. Novel and efficient molecular targets are therefore required for improving diagnosis, survival prediction, and treatment outcomes. Additionally, some studies have shown that immunity is highly associated with glioma progression. Our study aimed to investigate the clinicopathological features, prognostic significance, and immunotherapeutic targetability of ELK3, a member of the erythroblast transformation-specific transcription factor family, in glioma using bioinformatics analyses. ELK3 transcript levels in glioma tissues were evaluated using the Gene Expression Omnibus and The Cancer Genome Atlas databases. Clinical and transcriptomic data of The Cancer Genome Atlas glioma patients were analyzed to identify the molecular and clinical characterizations of ELK3. The prognostic significance of ELK3 was assessed using Cox regression and Kaplan–Meier analysis. The biological pathways related to ELK3 expression were identified by gene set enrichment analysis. The relationships between ELK3 and inflammatory responses, immune cell infiltration, and immune checkpoints were explored using canonical correlation analysis and gene set variation analysis. ELK3 was upregulated in gliomas, and its high expression was correlated with advanced clinicopathologic features and unfavorable prognosis. Gene set enrichment analysis revealed that several immune-related pathways were tightly linked to high ELK3 expression. gene set variation analysis and correlograms demonstrated that ELK3 was robustly associated with inflammatory and immune responses. Correlation analyses indicated that ELK3 was positively associated with infiltrating immune cells and synergistic with several immune checkpoints. ELK3 may serve as a novel marker of poor prognosis and a potential immunotherapeutic target in glioma. Lippincott Williams & Wilkins 2022-07-29 /pmc/articles/PMC9333475/ /pubmed/35905257 http://dx.doi.org/10.1097/MD.0000000000029544 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.
spellingShingle Research Article
Xu, Hao
Zhang, Li
Gao, Jin
Wang, Jiajing
Wang, Yihao
Xiao, Dongdong
Chai, Songshan
Molecular and clinical features of a potential immunotherapy target ELK3 in glioma
title Molecular and clinical features of a potential immunotherapy target ELK3 in glioma
title_full Molecular and clinical features of a potential immunotherapy target ELK3 in glioma
title_fullStr Molecular and clinical features of a potential immunotherapy target ELK3 in glioma
title_full_unstemmed Molecular and clinical features of a potential immunotherapy target ELK3 in glioma
title_short Molecular and clinical features of a potential immunotherapy target ELK3 in glioma
title_sort molecular and clinical features of a potential immunotherapy target elk3 in glioma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9333475/
https://www.ncbi.nlm.nih.gov/pubmed/35905257
http://dx.doi.org/10.1097/MD.0000000000029544
work_keys_str_mv AT xuhao molecularandclinicalfeaturesofapotentialimmunotherapytargetelk3inglioma
AT zhangli molecularandclinicalfeaturesofapotentialimmunotherapytargetelk3inglioma
AT gaojin molecularandclinicalfeaturesofapotentialimmunotherapytargetelk3inglioma
AT wangjiajing molecularandclinicalfeaturesofapotentialimmunotherapytargetelk3inglioma
AT wangyihao molecularandclinicalfeaturesofapotentialimmunotherapytargetelk3inglioma
AT xiaodongdong molecularandclinicalfeaturesofapotentialimmunotherapytargetelk3inglioma
AT chaisongshan molecularandclinicalfeaturesofapotentialimmunotherapytargetelk3inglioma